Please login to the form below

Not currently logged in
Email:
Password:

Intercept

This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.

Better together when buying medicines? Taking stock of the BeNeLuxA initiative

Better together when buying medicines? Taking stock of the BeNeLuxA initiative

was subsequently updated) for Vertex’s cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor), Intercept’s Ocaliva (obeticholic acid) for primary biliary cholangitis and for Biogen’s Spinraza (nusinersen) for spinal muscular atrophy

Latest news

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    Among these, Intercept’s Ocaliva (obeticholic acid) is already approved to treat rare liver disease primary biliary cirrhosis, and is in phase 3 for NASH patients with cirrhosis, while Gilead Sciences

  • Gilead NASH drug clears mid-stage trial, but rivals are looming Gilead NASH drug clears mid-stage trial, but rivals are looming

    Positive results to challenge Intercept in emerging disease area. Gilead has new data backing up its liver disease candidate GS-9674 in non-alcoholic steatohepatitis (NASH), tipped as one of the ... The new data shows Gilead’s drug is working as

  • Novartis and Pfizer to collaborate on NASH combinations Novartis and Pfizer to collaborate on NASH combinations

    needs.”. Other companies such as Intercept, Allergan and Gilead have FXR agonists in their pipelines, but Gilead suffered a disappointment when its candidate failed to show efficacy a recent phase 2 ... Intercept’s Ocaliva (obeticholic acid, an FXR

  • Orphan drugs dominate UK Prix Galien shortlist, medtech debuts Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

    Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).

  • Intercept hit hard as FDA issues Ocaliva safety notice Intercept hit hard as FDA issues Ocaliva safety notice

    Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in December. ... Intercept can muster approvals in additional indications such as non-alcoholic steatohepatitis (NASH) for which it is in

More from news
Approximately 6 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics